Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
Danve A, Vadhariya A, Lisse J, Cholayil A, Bansal N, Bello N, Bakewell C. Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study. Rheumatology And Therapy 2024, 11: 1333-1345. PMID: 39162898, PMCID: PMC11422398, DOI: 10.1007/s40744-024-00710-0.Peer-Reviewed Original ResearchHealth care resource utilizationFollow-up periodTumor necrosis factor-alpha inhibitorsTreatment patternsAxial spondyloarthritisPre-indexMethodsThis retrospective cohort studyBiologic-experienced patientsCharlson Comorbidity Index scoreRetrospective cohort studyClaims database studyIntroductionReal-world dataAssessed patient demographicsComorbidity Index scoreHigher comorbidity burdenProportion of daysBiologic-experiencedPatient demographicsClinical characteristicsIxekizumabIndex dateCohort studyPharmacy enrollmentEmergency room visitsAxSpAIs yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas